LEXICON PHARMACEUTICALS INC (LXRX)
US5288723027 - Common Stock
LEXICON PHARMACEUTICALS INC
NASDAQ:LXRX (12/1/2023, 7:09:02 PM)
After market: 1.12 -0.03 (-2.61%)1.15
+0.09 (+8.49%)
Company Profile
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 135 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Its LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of SGLT2 in the kidney.
Company Info
LEXICON PHARMACEUTICALS INC
8800 Technology Forest Place, 8800 Technology Forest Place
The Woodlands TEXAS 77381
P: 12818633000.0
CEO: Lonnel Coats
Employees: 135
Website: https://www.lexpharma.com/
LXRX News
The PROGRESS study marks initiation of the late-stage development program for AAK1 inhibitor LX9211, with potential to become the first new, non-opioid...
THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following...
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant...
THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies...
24 days ago - Seeking AlphaLexicon Pharmaceuticals GAAP EPS of -$0.21 in-line, revenue of $0.16M misses by $1.9M (NASDAQ:LXRX)Lexicon Pharmaceuticals reports Q3 GAAP EPS of -$0.21 in-line, but revenue of $0.16M misses by $1.9M.
Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with...
LXRX Twits
Here you can normally see the latest stock twits on LXRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
